Previous 10 | Next 10 |
FDA issues Complete Response Letter (CRL) for ONS-5010 BLA based on CMC and need for further confirmatory clinical evidence Outlook Therapeutics working with FDA to address the Agency’s issues Company to host conference call and webcast, today, August 30 at 8:30 AM ET ...
2023-08-29 08:32:57 ET Tivic Health Systems ( TIVC ) +112% . iCoreConnect ( ICCT ) +26% . Globalstar ( GSAT ) +19% Appoints Dr. Paul Jacobs as Chief Executive Officer; Announces Agreement to License XCOM Labs Technology. Bionomics Limited ( ...
2023-08-28 10:05:32 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-28 08:43:42 ET Hersha Hospitality ( HT ) +57% trust agrees to $1.4B buyout by KSL. LQR House ( LQR ) +40% . GD Culture Group ( GDC ) +26% Group Limited Expands Grids of the Future Portfolio with TikTok to Drive Growth of Live-Streaming E-Com...
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) ISELIN, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (...
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that Russell Trenary, Pre...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
2023-07-07 07:44:52 ET BTIG technical strategist Jonanthan Krinsky is expecting a retracement for the broader market in the second half of the year following the strong gains so far. "If the year was over right now, it would be the NDX’s ( COMP.IND ) ( QQQ ) ninth best ye...
2023-06-10 01:06:36 ET Summary OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developments stop me from being overly enthusiastic. Outlook Therapeutics ( OTLK ) is develo...
2023-06-06 13:59:07 ET Shares of Outlook Therapeutics (NASDAQ: OTLK) were up 6.3% early Tuesday afternoon after rising as much as 16% earlier in the day. The stock went past $2 a share, reaching a 52-week high in the morning at $2.03 before falling back. It was the second consecutiv...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...